Gilead Sciences Inc. has announced a significant step forward in its mission to combat HIV with the recent positive EU-M4all opinion for lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor, intended for use as pre-exposure prophylaxis (PrEP). This approval facilitates accelerated regulatory submissions in high-incidence, resource-limited countries, enabling Gilead to pursue swift registrations by the end of 2025 in nations such as Botswana, Kenya, and Vietnam, among others. Gilead has already submitted a filing in South Africa. The company, in partnership with the U.S. State Department and PEPFAR, aims to deliver lenacapavir to up to two million people in countries supported by PEPFAR and the Global Fund over the next three years. This development is part of Gilead's broader access strategy, which includes royalty-free agreements with six generic manufacturers to serve 120 high-incidence countries.